Vinay Prasad has been reinstated to his previous role as head of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA), overseeing vaccines, gene therapy, and blood product regulation. This return comes less than two weeks after his abrupt resignation, which followed pressure from conservative allies of President Donald Trump, biotech executives, and patient groups. Prasad's ouster was reportedly influenced by online smears and political criticism, including from prominent Trump supporters. His reinstatement was reportedly supported by FDA veteran Marty Makary and has sparked uncertainty within the biotech community, with shares in related companies falling after news of his return. The FDA's internal dynamics remain unclear, with questions about staff notifications and recent personnel changes. Prasad's return signals a potentially broader shift in FDA leadership and policy direction under the current administration, which has elevated critics of the agency. The episode highlights ongoing tensions within the agency related to vaccine and gene therapy regulation and the influence of political and industry stakeholders.